CELESTICA INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data CELESTICA INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2017	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	6,047	6,143	6,633	5,888	5,748	5,635	7,250	7,961	9,646	12,391
Cost of revenue	5,617	5,724	6,203	5,504	5,311	5,148	6,600	7,207	8,612	10,897
Gross profit	430	419	431	385	438	487	650	754	1,034	1,494
Research and development	24.9	26.2	28.8	28.4	29.9	38.4	46.3	60.9	78	118
Selling, general and administrative	211	203	219	227	231	245	267	303	294	260
Operating income	159	143	106	149	128	168	289	338	599	1,041
Interest expense	10	10.1	24.4	49.5	37.7	31.7	51.7	78.9	52.1	52.6
Interest income	14.3	0	0
Other non-operating income							1.5	46.6	-15	-4.9
Pre-tax income	163	133	81.9	99.8	90.2	136	239	306	532	983
Income tax	24.7	27.6	-17	29.5	29.6	32.1	59	61.6	104	151
Net income	138	106	98.9	70.3	60.6	104	180	244	428	833
EBITDA							405	469	751	1,216
EPS, basic	1.21	0.92	0.88	0.67	0.58	1.01	1.46	2.03	3.62	7.22
EPS, diluted	1.19	0.90	0.87	0.66	0.58	1.01	1.46	2.03	3.61	7.16
Shares, basic (weighted)							124	120	118	115
Shares, diluted (weighted)							124	120	119	116

Balance sheet

	FY2017	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	557	515	422	480	464	394	375	370	423	596
Inventory	891	824	1,090	992	1,092	1,697	2,350	2,104	1,761	2,188
Other current assets								228	259	252
Total current assets	2,347	2,477	2,824	2,592	2,737	3,435	4,327	4,511	4,512	5,673
Property, plant and equipment	303	324	365	355	333	339	372	524	537	586
Lease right-of-use assets	11	10.5	10.1	104	101	114	139	108	124	124
Goodwill	23.2	23.2	198	198	199	324	322	322	341	333
Intangible assets	25.5	21.6	284	251	229	382	347	318	308	266
Other non-current assets								51.1	78.2	74.1
Total assets	2,822	2,964	3,738	3,561	3,664	4,667	5,628	5,891	5,988	7,213
Accounts payable								1,298	1,295	1,866
Accrued liabilities								207	241	293
Deferred revenue								905	512	407
Short-term debt								27	26.5	26
Total current liabilities	1,246	1,267	1,620	1,481	1,578	2,254	3,055	3,221	3,021	3,940
Long-term debt								648	770	751
Lease liabilities			7.2	87.7	90.5	104	127	83.4	109	108
Other non-current liabilities									167	176
Total liabilities	1,584	1,594	2,405	2,205	2,255	3,204	3,950	4,120	4,092	4,997
Total debt			159	0	0	0		675	797	777
Paid-in capital	863	863	907	983	975	1,030	1,064	1,031	798	343
Retained earnings	-1,632	-1,526	-1,482	-1,420	-1,369	-1,256	-1,077	-852	-424	409
Treasury stock								-80.1	-92.9	-154
Other comprehensive income								-0.2	-17.6	-1.7
Shareholders' equity	1,239	1,370	1,332	1,356	1,409	1,462	1,676	1,771	1,896	2,216
Total equity	1,258	1,370	1,332	1,356	1,409	1,463	1,678	1,769	1,896	2,216
Total liabilities and equity	2,822	2,964	3,738	3,561	3,664	4,667	5,628	5,891	5,988	7,213
Shares outstanding									116	115

Cash flow statement

	FY2017	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	138	106	98.9	70.3	60.6	104	180	244	428	833
Depreciation and amortization							116	131	152	176
Stock-based compensation							51	55.6	57.4	69.8
Deferred income tax							-27.9	-3.6	-31.9	-68.4
Change in receivables							-133	-402	-271	-569
Change in inventory							-717	245	344	-427
Cash from operations	173	127	33.1	345	240	227	211	326	474	660
Capital expenditures							-109	-125	-171	-201
Acquisitions							0	0	-36.1	0
Cash from investing	-64	-89.3	-546	38.7	-51	-364	-109	-122	-213	-204
Debt issued	40	0
Debt repaid	-75	-40			0
Stock issued	4.1	13.6	0.4	0	0	0.2	0.2	0.3	3.9	0.3
Share buybacks							-34.6	-35.6	-152	-153
Cash from financing	-97.4	-79.7	419	-326	-204	67.7	-122	-208	-209	-284
Net change in cash	11.9	-42	-93.2	57.5	-15.7	-69.8	-19.5	-4.1	52.9	172
Free cash flow							102	201	303	458
Interest paid							52.9	68.8	52.9	54.1
Income taxes paid	-11.9	30.8	44.8	21	27.8	39.4	65.1	78.4	106	175

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $365.44 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	12.0%	Gross profit / revenue.
Operating margin	8.8%	Operating income / revenue.
EBITDA margin	9.9%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	8.4%	Pre-tax income / revenue.
Net margin	7.2%	Net income / revenue.
FCF margin	3.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	7.3%	Cash from operations / revenue.
Effective tax rate	14.8%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	45.0%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	11.4%	Net income / average total assets.
Return on invested capital (ROIC)	42.4%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	1.0%	Research and development expense / revenue.
SG&A / revenue	1.8%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.5%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	4.0%	Capital expenditures / revenue.
D&A / revenue	1.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	28.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	19.6%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	16.6%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	44.5%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	32.0%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	27.8%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	73.7%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	53.2%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	52.1%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	61.9%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	44.3%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income growth, 1y	94.5%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	66.6%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	68.9%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	98.3%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	69.9%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	65.2%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	39.2%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	46.2%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	22.4%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	51.3%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	65.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y	16.9%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	9.8%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	9.5%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	20.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	8.6%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	14.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-2.1%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-2.0%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.23x	Current assets / current liabilities.
Quick ratio	0.09x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.09x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.33x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	8.3%	Total debt / total assets.
Liabilities / assets	74.7%	Total liabilities / total assets.
Net debt	$274.7M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	0.18x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	21.9x	Operating income / interest expense.
Working capital	$1.39B	Current assets - current liabilities.
Goodwill and intangibles / assets	5.9%	(Goodwill + intangible assets) / total assets.
Tangible book value	$1.90B	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.59x	Revenue / average total assets.
Fixed asset turnover	15.2x	Revenue / average property, plant and equipment.
Inventory turnover	4.04x	Cost of revenue / average inventory.
Days inventory	90 days	365 x average inventory / cost of revenue.
Days payables	102 days	365 x average accounts payable / cost of revenue.
FCF conversion	46.5%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	54.7%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$9.61	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$134.20	Revenue / diluted weighted shares.
FCF per share	$4.46	Free cash flow / diluted weighted shares.
Operating cash flow per share	$9.85	Cash from operations / diluted weighted shares.
Book value per share	$21.34	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$16.37	Tangible book value / shares outstanding.
Cash per share	$4.61	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	11.2%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$42.02B	Share price x shares outstanding.
Enterprise value	$42.29B	Market cap + total debt - cash - short-term investments.
P/E	37.6x	Market cap / net income. Only when net income is positive.
P/S	2.69x	Market cap / revenue.
P/B	16.9x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	22.1x	Market cap / tangible book value, when positive.
P/FCF	81.0x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	36.7x	Market cap / cash from operations, when positive.
EV/Sales	2.71x	Enterprise value / revenue.
EV/EBIT	30.9x	Enterprise value / operating income, when both are positive.
EV/EBITDA	27.3x	Enterprise value / EBITDA, when both are positive.
EV/FCF	81.5x	Enterprise value / free cash flow, when both are positive.
FCF yield	1.2%	Free cash flow / market cap.
Earnings yield	2.7%	Net income / market cap (the inverse of P/E).
Shareholder yield	0.1%	(Dividends paid + share buybacks) / market cap.
PEG	0.54x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was CELESTICA INC's revenue in fiscal 2025?

CELESTICA INC reported revenue of $12.39B for fiscal 2025, 28.5% higher than the year before.

Was CELESTICA INC profitable in fiscal 2025?

Yes. Net income was $832.5M, a net margin of 6.7%.

How much free cash flow did CELESTICA INC generate in fiscal 2025?

Cash from operations of $659.5M minus capital expenditures of $201.2M left free cash flow of $458.3M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to CELESTICA INC